Cavidi: Helping control the spread of HIV
and other viruses

When the HIV/AIDS pandemic hit in the early 1980s little was known about this fast spreading and deadly virus. The lack of knowledge led to a lot of misinformation about the disease, creating panic and contributing to even greater loss of life among people all over the world.

 

Fortunately over the years, extensive study of HIV/AIDS has led to a deep understanding of the virus and a diagnosis that was once considered a death sentence is now treatable. One of the key discoveries is that by managing a patient’s Viral Load using antiretroviral (ARV) therapy, those with the disease can lead long, full lives. This viral repression therapy also reduces the ability to transmit the virus to others.

 

The first step in managing a patient’s viral load is properly measuring it, which used to require taking samples and sending them to high tech labs for analysis, a virtual impossibility in many developing countries where the disease spreads fastest. Fortunately, Cavidi, a Swedish biotech company founded as a spinoff from Uppsala University has developed a testing protocol that can be used anywhere in the world.

 

Cavidi’s HIV diagnostics system focuses on quantifying Reverse Transcriptase activity to provide a highly accurate picture of what HIV is doing inside a patient’s body. Their products enable efficient management of anti-HIV drugs (ARV therapy) so that people living with HIV can live a normal lifespan, reducing the cost of treatment and the spread of HIV. Cavidi also provides tools and kits for virus research to many of the world’s leading labs.

 

Cavidi’s expertise is based on understanding viruses and using that knowledge to create research tools and clinical diagnostics. Today their focus is on HIV but our methods and expertise are being applied to other viruses including COVID-19, especially with their new ZIVA™ System.

 

ZIVA is a fully-automated viral load monitoring system purpose-built to meet the requirements of decentralized labs like those in district hospitals. Its unique Reverse Transcriptase (RT) technology produces gold-standard results for decentralized testing. ZIVA™ is designed with simplicity in mind, so with minimal training, technicians can load samples, run the tests with the push of a button, and get results quickly.

 

The ZIVA system works in any market and any size lab thanks to its ease of use, the affordability of the tests, and high throughput. Whether in a regional hospital in developing country, or a modern urban medical center, once a unit is deployed, it typically performs 12,000 tests per year up to a maximum capacity of 25 000 tests if needed.

 

Cavidi’s technology has been proven in over 500,000 tests, published in 60 peer reviewed journals. It is protected with over 100 global patents around 5 patent families and is ISO compliant through 2021. Cavidi is ready to scale into more markets and adapt their systems to test for immunity to other viruses, including coronaviruses like COVID-19. 

 

For more information about Cavidi and their ground-breaking viral diagnostic technology, visit cavidi.se or contact us and we’ll arrange a meeting with their executive team.

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as "expects", "will", "anticipates", "estimates", "believes", or by statements indicating certain actions "may", "could", "should" or "might" occur.

© 2020 Family Office Research, Consulting & Events All Rights Reserved.